Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.

EBioMedicine - 1 Oct 2015

Widschwendter Martin, Burnell Matthew, Fraser Lindsay, Rosenthal Adam N, Philpott Sue, Reisel Daniel, Dubeau Louis, Cline Mark, Pan Yang, Yi Ping-Cheng, Gareth Evans D, Jacobs Ian J, Menon Usha, Wood Charles E, Dougall William C

Abstract excerpt

Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANKL/osteoprotegerin (OPG) signalling. We analysed serum levels of RANKL, OPG, RANKL/OPG complex, oestradiol (E2), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA2
Share to Hereditary Breast and Ovarian Cancer Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormones

Share to Macaca fascicularis

Share to Osteoprotegerin

Share to Patient Outcome Assessment

Share to Postmenopause

Share to RANK Ligand

Source

Open in PubMed Open full text

Identifiers

PMID: 26629528
DOI: 10.1016/j.ebiom.2015.08.037
PMCID: PMC4634624

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.PMID 26629528Read ↗

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Semantic proximity Read ↗

RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.Semantic proximity Read ↗

The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.Semantic proximity Read ↗

Genetic polymorphism of the OPG gene associated with breast cancer.Semantic proximity Read ↗

RANKL/RANK: from bone loss to the prevention of breast cancer.Semantic proximity Read ↗

RANKL/RANK control Brca1 mutation- .Semantic proximity Read ↗

RANKL and CSF-1 are elevated in periovulatory follicular fluid of BRCA1 mutation carriers and increase proinflammatory signaling in fallopian tube epithelial cells.Semantic proximity Read ↗

Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.Semantic proximity Read ↗

RANKL and RANK: From Mammalian Physiology to Cancer Treatment.Semantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

RANK–RANKL signalling in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.